Encompass Health (HSOA) Stock Forecast & Price Target

2 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

HSOA Analyst Ratings

Strong Buy

9 Buy

0 Hold

0 Sell

Based on 9 analysts giving stock ratings to

Encompass

Health

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

HSOA Stock 12 Month Forecast

Average Price Target

€126.21

▲(22.53% Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Encompass Health in the last 3 months. The average price target is €126.21 with a high forecast of €132.69 and a low forecast of €119.85. The average price target represents a 22.53% change from the last price of €103.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"77":"€77","91":"€91","105":"€105","119":"€119","133":"€133"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":132.68923335,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€132.69</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":126.20763946285713,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€126.21</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":119.8483398,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€119.85</span>\n  </div></div>","useHTML":true}}],"tickPositions":[77,91,105,119,133],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,96,98.82224871923077,101.64449743846154,104.46674615769231,107.28899487692307,110.11124359615384,112.93349231538461,115.75574103461538,118.57798975384615,121.40023847307691,124.22248719230768,127.04473591153845,129.86698463076922,{"y":132.68923335,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,96,98.32366457406593,100.64732914813186,102.9709937221978,105.29465829626373,107.61832287032966,109.9419874443956,112.26565201846154,114.58931659252747,116.9129811665934,119.23664574065933,121.56031031472526,123.88397488879119,{"y":126.20763946285713,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,96,97.83448767692308,99.66897535384615,101.50346303076924,103.33795070769231,105.17243838461539,107.00692606153846,108.84141373846154,110.67590141538462,112.51038909230769,114.34487676923078,116.17936444615385,118.01385212307693,{"y":119.8483398,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":95.319,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.269,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":106.402,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.435,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.441,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.491,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.698,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.652,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.842,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.334,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89.829,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€132.69

Average Price Target€126.21

Lowest Price Target€119.85

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

David S Macdonald

Truist Financial

€128.41

Buy

24.67%

Upside

Reiterated

08/11/26

Truist Financial Keeps Their Buy Rating on Encompass Health (EHC)

Ann Hynes

Mizuho Securities

€119.85

Buy

16.36%

Upside

Reiterated

08/11/26

Encompass Health (EHC) Receives a Buy from Mizuho Securities

Ryan Langston

TD Cowen

€107.01→€119.85

Buy

16.36%

Upside

Assigned

08/10/26

Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (NASDAQ: MIRM) and Encompass Health (NYSE: EHC)

A.J. Rice

UBS

€128.41→€132.69

Buy

28.82%

Upside

Assigned

08/07/26

Encompass Health price target raised to $155 from $150 at UBSEncompass Health price target raised to $155 from $150 at UBS

Parker Snure

Raymond James

€111.29→€128.41

Buy

24.67%

Upside

Reiterated

08/07/26

Encompass Health price target raised to $150 from $130 at Raymond JamesEncompass Health price target raised to $150 from $130 at Raymond James

Joanna Gajuk

Bank of America Securities

€128.41→€130.98

Buy

27.16%

Upside

Reiterated

08/06/26

Bank of America Securities Sticks to Its Buy Rating for Encompass Health (EHC)

Andrew Mok CFA

Barclays

€119.85→€123.27

Buy

19.68%

Upside

Reiterated

08/06/26

Barclays Sticks to Its Buy Rating for Encompass Health (EHC)

Jared Haase

William Blair

―

Buy

―

Reiterated

08/05/26

Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (NASDAQ: MIRM) and Encompass Health (NYSE: EHC)

Matthew Gillmor CFA

KeyBanc

―

Buy

―

Reiterated

06/12/26

Analysts' Top Healthcare Picks: Amgen (AMGN), Enliven Therapeutics (ELVN)

Unknown Analyst

Stephens

Not Ranked

Stephens

€119.85

Buy

16.36%

Upside

Reiterated

05/04/26

Stephens Reaffirms Their Buy Rating on Encompass Health (EHC)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

David S Macdonald

Truist Financial

€128.41

Buy

24.67%

Upside

Reiterated

08/11/26

Truist Financial Keeps Their Buy Rating on Encompass Health (EHC)

Ann Hynes

Mizuho Securities

€119.85

Buy

16.36%

Upside

Reiterated

08/11/26

Encompass Health (EHC) Receives a Buy from Mizuho Securities

Ryan Langston

TD Cowen

€107.01→€119.85

Buy

16.36%

Upside

Assigned

08/10/26

Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (NASDAQ: MIRM) and Encompass Health (NYSE: EHC)

A.J. Rice

UBS

€128.41→€132.69

Buy

28.82%

Upside

Assigned

08/07/26

Encompass Health price target raised to $155 from $150 at UBSEncompass Health price target raised to $155 from $150 at UBS

Parker Snure

Raymond James

€111.29→€128.41

Buy

24.67%

Upside

Reiterated

08/07/26

Encompass Health price target raised to $150 from $130 at Raymond JamesEncompass Health price target raised to $150 from $130 at Raymond James

Joanna Gajuk

Bank of America Securities

€128.41→€130.98

Buy

27.16%

Upside

Reiterated

08/06/26

Bank of America Securities Sticks to Its Buy Rating for Encompass Health (EHC)

Andrew Mok CFA

Barclays

€119.85→€123.27

Buy

19.68%

Upside

Reiterated

08/06/26

Barclays Sticks to Its Buy Rating for Encompass Health (EHC)

Jared Haase

William Blair

―

Buy

―

Reiterated

08/05/26

Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (NASDAQ: MIRM) and Encompass Health (NYSE: EHC)

Matthew Gillmor CFA

KeyBanc

―

Buy

―

Reiterated

06/12/26

Analysts' Top Healthcare Picks: Amgen (AMGN), Enliven Therapeutics (ELVN)

Unknown Analyst

Stephens

Not Ranked

Stephens

€119.85

Buy

16.36%

Upside

Reiterated

05/04/26

Stephens Reaffirms Their Buy Rating on Encompass Health (EHC)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

ODTXOdyssey Therapeutics, Inc.

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

GPCRStructure Therapeutics, Inc. Sponsored ADR

AMLXAmylyx Pharmaceuticals Inc

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Encompass Health

3 Months

Ann HynesMizuho Securities

Success Rate

18/27 ratings generated profit

Average Return

+5.06%

Copying Ann Hynes's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +5.06% per trade.

1 Year

David S MacdonaldTruist Financial

Success Rate

23/26 ratings generated profit

Average Return

+22.43%

Copying David S Macdonald's trades and holding each position for 1 Year would result in 88.46% of your transactions generating a profit, with an average return of +22.43% per trade.

2 Years

Ann HynesMizuho Securities

Success Rate

25/27 ratings generated profit

Average Return

+41.80%

Copying Ann Hynes's trades and holding each position for 2 Years would result in 92.59% of your transactions generating a profit, with an average return of +41.80% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

HSOA Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, HSOA has received 14 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. HSOA average Analyst price target in the past 3 months is 126.21.

Each month's total comprises the sum of three months' worth of ratings.

HSOA Financial Forecast

HSOA Earnings Forecast

Next quarter’s earnings estimate for HSOA is €1.18 with a range of €1.08 to €1.26. The previous quarter’s EPS was €1.34. HSOA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year HSOA has Performed in-line its overall industry.

HSOA Sales Forecast

Next quarter’s sales forecast for HSOA is €1.39B with a range of €1.38B to €1.40B. The previous quarter’s sales results were €1.38B. HSOA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year HSOA has Performed in-line its overall industry.

HSOA Stock Forecast FAQ

What is DE:HSOA’s average 12-month price target, according to analysts?

Based on analyst ratings, Encompass Health’s 12-month average price target is 126.21.

What is DE:HSOA’s upside potential, based on the analysts’ average price target?

Encompass Health has 22.53% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Encompass Health a Buy, Sell or Hold?

Encompass Health has a consensus rating of Strong Buy, which is based on 9 buy ratings, 0 hold ratings and 0 sell ratings.

What is Encompass Health’s share price target?

The average share price target for Encompass Health is 126.21. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €132.69 ,and the lowest forecast is €119.85. The average share price target represents 22.53% Increase from the current price of €103.

What do analysts say about Encompass Health?

Encompass Health’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of Encompass Health?

To buy shares of DE:HSOA, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Encompass Health (HSOA) Stock Forecast & Price Target

HSOA Analyst Ratings

HSOA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Encompass Health

HSOA Analyst Recommendation Trends

HSOA Financial Forecast

HSOA Earnings Forecast

HSOA Sales Forecast

HSOA Stock Forecast FAQ

Detailed List of Analyst Forecasts